Mahmoud Mahmoudian

Dr. Mahmoudian’s career spans 20 years in biotech, pharma, chemical sectors, catalyzing growth and innovation – developed 8 FDA approved drugs from discovery to patients, $15B sales.  Closed 50 deals, buy/ sell side, discovery to Ph-III (cell therapy, vaccines, biologics, small molecules) in immuno-oncology, immunotherapy, inflammation, rare/ autoimmune diseases, and anti-infectives ($200B markets).

Dr. Mahmoudian joined Purdue Pharma as Vice President, Head of Innovation Hub/ Business Development Licensing worldwide to incubate, build and commercialize future pipeline.  At Ferring Pharmaceuticals, he served as Vice President, Head of Innovative Medicines leading cross-functional scientific/ commercial due diligence teams to scout/ evaluate and negotiate novel products/ platforms with startups/ academia/ venture capital.  At Merck he was Managing Director of External Research in vaccines, biologics and biosimilars (Merck BioVentures).  At Dow he was Chief Innovation Officer/ Chair of Executive Committee for growth, overseeing all of research/ strategic alliances in five sites (US, UK, France, China, Japan) generating $600M sales.  At Eastman he was Chief Biotechnology Officer responsible for R&D, partnering, managing growth and development of its BioProducts portfolio.  He launched his career with GlaxoSmithKline, where he held a variety of research, development, and management roles of increasing responsibility, leading global R&D teams.  Dr. Mahmoudian is an Executive In Residence at Columbia and Princeton.  He earned his PhD in Biotechnology from Imperial College, London UK.